The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.

The trial will test the drug in metastatic castration-resistant prostate cancer patients with low alkaline phosphatase levels, a marker of less advanced disease.

The company and the German university hospital will initially focus on developing screening programs and precision therapies for heart diseases.

The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

After an abnormal NIPT finding in a pregnant woman, a maternal-fetal medicine doctor orders a second NIPT, against ...

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is ...

NEW YORK – RedHill Biopharma has begun recruiting patients with metastatic castration-resistant prostate cancer to a Phase II trial testing the combination of opaganib, its small molecule sphingosine ...

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

Rutgers New Jersey Medical School has rolled out routine blood tests for the cardiovascular biomarker at another one of its ...